Clinical Data Parsortix study shows promise for ADC target detection PharmaTimesResearchers highlight minimally invasive monitoring potentialOncologyRead full story pharminent August 3, 2026 (Last updated: August 3, 2026) PharmaTimes Researchers highlight minimally invasive monitoring potential Oncology Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Novo Nordisk’s Ziltivekimab Misses Primary Endpoint in Pivotal Cardiovascular TrialNext: AstraZeneca and Bristol Myers Squibb Reported to Have Held Mega-Merger Talks Related Stories Clinical Data Novo setback casts doubt on a new way to treat heart disease pharminent July 31, 2026 Clinical Data Altimmune rises as GLP-1/GIP drug curbs heavy drinking in mid-stage study pharminent July 28, 2026 Clinical Data Arrowhead hits ‘best-case scenario’ with latest results for fat-lowering drug pharminent July 22, 2026
